FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma

On January 19, 2024, the Food and Drug Administration approved erdafitinib (Balversa, Janssen Biotech) for locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy.

Source: FDA Center for Drug Evaluation and Research - What's New - January 19, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news